VarmX (www.varmx.com) is a young Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The VarmX program has gained significant interest in the investment community and a very successful Series B financing round of €32 mill. was closed in 2020.
This round was followed by a Series B2 round of €32 mill. in May 2023 allowing the company to further progress the lead program towards Investigational New Drug (IND) approval and prepare for pivotal trials.
Company Details
- Employees
- 27
- Founded
- -
- Address
- Middelweg 38b, Leiden,2312 Kj,netherlands
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.varmX.com
- HQ
- Leiden
Varmx Questions
Varmx's website is http://www.varmX.com
Varmx's LinkedIn profile is https://nl.linkedin.com/company/varmx
Varmx has
27 employees.
View email and phone details for 27
employees at Varmx.
Varmx's industry is
Biotechnology Research
Varmx's top competitors are
Qdi Systems,
Veridi Technologies Bv,
Everox,
Delft Circuits,
Leyden Labs,
Carbonx,
Deeploy,
Nextkidney,
Brineworks,
Astrape Networks.
Varmx's categories are Biotechnology Research
Varmx's founding year is 2016
